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THE POTENTIAL BENEFITS AND DRAWBACKS 
OF ALLOWING DIRECT-TO-CONSUMER 
ADVERTISING OF PHARMACEUTICALS 
IN EUROPE
Dickson AJ
Consultant Health Economist, Northallerton, United Kingdom.
Whether to legalise direct-to-consumer advertising (DTCA),
the authorised advertising of prescription drugs direct to
the consumer, within the European Union (EU) is often
discussed. But how would allowing DTCA help EU gov-
ernments looking for solutions to rising costs, rising pa-
tient expectations, loss of public confidence and ageing
populations? This poster summarises the main arguments
for and against the EU legalising DTCA.
OBJECTIVES: To explore the arguments for and against
allowing the use of DTCA in EU states; to determine the
validity of the propounded arguments, by evaluating ac-
tual data which highlights the effects of introducing
DTCA in the US and New Zealand.
METHODS: Using PubMed and a within-literature
search, a literature review of published information on
the arguments for and against DTCA, and DTCA’s asso-
ciated costs was undertaken.
RESULTS: Advocates believe DTCA will enable the
pharmaceutical industry to significantly improve the ef-
fectiveness of its marketing campaigns. DTCA’s oppo-
nents argue that health-care provider’s ability to ration
health care based on clinical need will be destroyed. US
data indicates that DTCA rose 38.5% in 1999 to
$US1.8bn, whilst in New Zealand expenditure rose
47.1% in 2000 to $US21.5m. DTCA has caused US retail
spending on prescriptions to soar. Yet in New Zealand
DTCA is credited with improving awareness, choice and
treatment of previously neglected conditions.
CONCLUSIONS: DTCA’s ability to allow the pharma-
ceutical industry to connect with its ultimate consumers
(patients) would lead to increased strains on European
health systems. But, the increased awareness that DTCA
will bring to currently neglected conditions (such as os-
teoarthritis in men) could lead to huge benefits to patients
quality-of-lives and help refocus changing health systems
towards patients needs. As such, DTCA could be part of
the solution to Europe’s health care crisis, but its introduc-
tion will bring to EU states as many headaches as it solves.
PHP27
THE RELATIONSHIP BETWEEN NATIONAL 
HEALTH INSURANCE EXPENDITURE AND THE 
BURDEN OF DISEASE- AN EVIDENCE-BASED 
STUDY IN TAIWAN
Liang LY
National Yang-Ming University, Taipei, Taiwan
OBJECTIVE: To examine the relation between actual
National health insurance expenditure and the burden of
36 specific-disease with regression model.
METHODS: Claims data were obtained from the bureau
of National health insurance and the vital registration
data were from the department of health in Taiwan. We
compare disease-specific expenditure with the burden of
this disease. Thirty-six major diseases included cancers,
DM, heart and cerebrovascular disease, hypertension, re-
spiratory disease, musculoskeletal disorder, congenital
anomalies, and injury. The disease burden was measured
by DALYs, years of life lost, disease prevalence, number
of outpatients and outpatient visits, and number of inpa-
tients in January 1998. Regression analyses were con-
ducted with logarithmic transformation.
RESULTS: The total national health expenditure and
DALYs is US$8.231 billion, and 1,500,166 person-years,
respectively. DALYs were strongly associated with dis-
ease prevalence (r  0.73 p  .001) and number of inpa-
tients(r  0.87 p  .001). There was relation between the
amount of expenditure per number of patients (inpatients
and outpatients) and disease prevalence (r  0.62 p 
0.001). Multiple regression analysis identified prevalence
and DALYs as the main determinants of expenditure per
number of patients (R20.474 and 0.16 respectively) af-





Richter A, Sherrill E, von Scheele B, Devlin P
Research Triangle Institute-Health Solutions (RTI-HS), 
Research Triangle Park, NC, USA
OBJECTIVE: This evidence-based review evaluates the
therapeutic comparability of COX-2-specific inhibitor
drugs, celecoxib and rofecoxib, for use in arthritis.
METHODS: A literature search identified 28 random-
ized clinical trials comparing the two coxibs to placebo
and to non-selective NSAID controls. Evidence tables
were compiled for common outcomes and meta-analyses
conducted. Efficacy was assessed on three subscales
(pain, stiffness, and physical function), and safety was
analyzed using broad measures such as withdrawals due
to adverse events.
RESULTS: Both coxibs improve arthritis symptoms com-
pared to placebo. The evidence collected here does not
suggest an efficacy advantage for either drug over non-
selective NSAIDs. In osteoarthritis, small statistically sig-
nificant differences were detected between rofecoxib and
celecoxib when compared to their respective placebo
groups but not when compared to active controls. The
magnitude of the differences was below a level consid-
ered clinically important. In rheumatoid arthritis, both
coxibs in high doses demonstrate proof of efficacy com-
parable to non-selective NSAIDs. Rofecoxib had a higher
incidence of edema/hypertension. Celecoxib-treated pa-
tients suffered more dyspepsia/abdominal pain. Both
were shown to have reduced incidence of ulcers com-
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pared to active controls. Meta-analyses did not find a dif-
ference between rofecoxib and celecoxib in broad safety
measures.
CONCLUSION: Caveats to this analysis include the po-
tential for selection and instrument bias. The two coxibs
show comparable overall efficacy and safety. However,
caution is advised in applying the results of aggregate anal-
yses at the individual patient level. Since the safety profiles
for the coxibs are somewhat different, arthritis treatment
should be individualized based on patient co-morbidities.
PAO2
ECONOMIC BURDEN AND LOSS IN QUALITY OF 
LIFE IN PATIENTS WITH OSTEOARTHRITIS
Lovas K1, Szende A2, Hodinka L3, Bàlint G3, Héjj G3
1Semmelweis University, Budapest, Hungary; 2MEDTAP 
International, Amsterdam, The Netherlands; 3National Institute 
of Rheumatology and Physiotherapy, Budapest, Hungary
OBJECTIVES: To measure quality of life and health-care
utilization related to osteoarthritis and to understand the
relationship among different parameters.
METHODS: 245 patients with osteoarthrosis (176 fe-
male) of mean age 64 years were recruited within a mus-
culoskeletal study in both primary care and rheumatol-
ogy outpatient settings in Hungary in 1999 and 2000.
Patients filled in both the generic EQ-5D quality-of-life
questionnaire and the disease-specific WOMAC ques-
tionnaire and reported resource utilization. Mean quality-
of-life and health-care-utilization values were reported
and correlation coefficients between different measure-
ments were analyzed.
RESULTS: Average EQ-5D index, EQ-5Dvas, WOMAC
(pain (A), stiffness (B), physical function (C)) scores were
0.42, 49.18, 9.28, 3.87, 36.32 respectively. Average an-
nual number of physiotherapy and spa treatment sessions
were 33.32 and 9.88, respectively. Average number of
GP and specialist visits were 31.4 and 8.54 annually. Pa-
tients spent a mean of nine days in hospital and they
spent 12.5 days in bed due to osteoarthritis. Active pa-
tients spent a mean of 6.7 days on sick leave. Statistically
significant correlation was observed between the follow-
ing: EQ-5D index and EQ-5Dvas; EQ-5D index and
WOMAC C; EQ-5Dvas and WOMAC C; days in bed
and EQ-5D index; days in bed and EQ-5Dvas; days in
bed and WOMAC C. Corresponding correlation coeffi-
cients were: 0.35; 0.59; 0.33; 0.35; 0.17; 0.24; re-
spectively (p  .01).
CONCLUSIONS: Results showed that osteoarthritis
leads to substantial loss in quality of life, important direct
medical costs, and substantial productivity loss among
active patients.
PAO3
COST OF CARE FOR MEMBERS WITH 
ARTHRITIS—A MANAGED CARE PERSPECTIVE
Schaffer M1, Howe A2, Mansukani S1
1Health Partners, Inc, Philadelphia, PA; 2Grady Health System, 
Atlanta, GA
OBJECTIVE: In order to assess the impact of interven-
tion programs to be implemented, a baseline assessment
of the burden of illness for arthritis is needed. Nearly one
third of Philadelphians receive their medical care through
Medicaid. To be representative of the population we
serve, we therefore set out to measure the incidence and
impact of arthritis in an inner city, Medicaid managed-
care population.
METHODS: We identified members continuously en-
rolled (per HEDIS definitions) during 1999 with paid
claims reflecting diagnoses indicative of arthritis. Primary
through quaternary diagnoses for arthritis (ICD-9CM
codes 095.6, 095.7, 095.8, 099.3, 136.1, 274, 277.2, 287.0,
344.6, 353.0, 354.0, 355.5, 357.1, 390, 391, 437.4,
443.0, 446, 447.6, 696.0, 710–716, 719.0, 719.2–719.9,
720–721, 725–727, 728.0–728.3, 728.6–728.9, 729.0–
729.1, and 729.4) were used to determine incidence. To-
tal amounts paid per claim were tallied. Arthritis-related
drugs were those defined as AHFS classes 12:20.00,
28:08.04, 28:08.08 and unclassified arthritis related agents.
Members’ demographic data was also obtained.
RESULTS: From a cohort of 73,948 members, we identi-
fied 8197 (11.1%) individuals with a medical claim for
arthritis. Females comprised 77.0% (1744) of these mem-
bers, greater than the norm for this population (p  .05).
The average age was 53.8 years. This population with ar-
thritis was composed of 46.8% African-Americans,
23.2% Caucasians, 23.7% Latinos, and 3.0% Asian-
Americans. Medical claims and arthritis-related drug
costs for this population totaled $5,328,406 ($650 per
identified member).
CONCLUSION: Effects of interventions cannot be mea-
sured until baseline information is assessed. It is hoped
that along with the data gathered here, an intervention
can be implemented citywide, the effects of which can be
measured. The diversity of Philadelphia’s population
should allow for differences that might exist among eth-
nic groups to be demonstrated. Managed care payers are
also responsible for drug expenditures. The costs for
some of these products are presented herein.
PAO4
THE COST-EFFECTIVENESS OF CELECOXIB 
COMPARED TO DICLOFENAC IN PATIENTS 
WITH RHEUMATOID ARTHRITIS IN POLAND
Orlewska E
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: to estimate the cost-effectiveness of cele-
coxib 0,2 g bid vs. diclofenac 75 mg bid in rheumatoid
arthritis (RA) patients in Poland and to identify whether
and to what extent celecoxib represents good use of
health-service resources.
METHODS: A decision analytic model in the Polish
